Crossref
Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.7968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Drugs in Dermatology, 2024. Verfasst von Advaitaa Ravipati und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Skin Neoplasms, United States Food and Drug Administration, Drug Approval.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Skin NeoplasmsUnited States Food and Drug AdministrationDrug ApprovalHumansMaleFemaleUnited StatesMiddle AgedAgedPyridinesAnilidesBasal Cell CarcinomaImmune Checkpoint InhibitorsAdverse Drug Reaction Reporting SystemsAlopeciaAdultAntibodies, Monoclonal, HumanizedCarcinoma, Squamous Cell
Substanzen
PyridinesAnilidesHhAntag691Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanized
Zitieren
APA
Ravipati, A., Pradeep, T., & Nouri, K. (2024). Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7968
Vancouver
Ravipati A, Pradeep T, Nouri K. Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.7968
BibTeX
@article{Ravipati2024,
author = {Ravipati, Advaitaa and Pradeep, Tejus and Nouri, Keyvan},
title = {Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.7968}
}
EUVIMED